Cas:73200-73-4 3-Phenyl-2-pyrazinol manufacturer & supplier

We serve Chemical Name:3-Phenyl-2-pyrazinol CAS:73200-73-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-Phenyl-2-pyrazinol

Chemical Name:3-Phenyl-2-pyrazinol
CAS.NO:73200-73-4
Synonyms:3-Phenyl-2-pyrazinol;3-phenylpyrazin-2-ol;2-pyrazinol, 3-phenyl-;2(1H)-Pyrazinone, 3-phenyl-
Molecular Formula:C10H8N2O
Molecular Weight:172.183
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:457.4±40.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.618
PSA:45.75000
Exact Mass:172.063660
LogP:0.78

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-Phenyl-2-pyrazinol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2(1H)-Pyrazinone, 3-phenyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-pyrazinol, 3-phenyl- Use and application,2(1H)-Pyrazinone, 3-phenyl- technical grade,usp/ep/jp grade.


Related News: In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase. 3-Phenyl-2-pyrazinol manufacturer The United States has suspended imports of dogs from more than 100 countries where there’s a high rabies risk. 3-Phenyl-2-pyrazinol supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 3-Phenyl-2-pyrazinol vendor Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. 3-Phenyl-2-pyrazinol factory Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.